A longevity or anti-aging drug for domestic dogs receives full regulatory approval before 2028.

Question

Six frontier AI models put this at 21% by 2 Nov 2029. Full reasoning from every model.

WillHappen.ai · Accepted Answer

21% — the median of 6 frontier models, resolving by 2029-11-02.

Answer

Gemini (Google): 18% — Conditional approval under FDA-CVM Expanded Conditional Approval is likely, but full NADA approval requires survival data that takes years. Loyal (LO-001/LO-002) has cleared reasonable expectation of effectiveness, but full NADA requires verified longitudinal mortality data. FDA-CVM standard review cycles take 180 days per section, leaving under 14 months to complete safety, manufacturing, and full efficacy dossiers. Early unblinded data showing definitive statistical separation in large-dog lifespan would be required to accelerate full approval before 2028.

Answer

Claude (Anthropic): 32% — Hinges on Loyal's LOY-002 reaching full FDA CVM approval (not just conditional) before late 2029. Loyal already has conditional approval pathway progress for LOY-002 targeting large/giant breed aging, with full approval possibly targeted around 2026-2028. FDA CVM's conditional licensing process allows marketing before full efficacy proof, so 'full approval' specifically is a higher bar that could slip past 2029. Veterinary drug approvals often face multi-year delays from additional safety/efficacy data requests, which could push timeline past the resolution date.

Answer

GPT (OpenAI): 63% — Loyal’s FDA-aligned pivotal studies and CVM’s willingness to accept aging as an approvable indication are decisive. Loyal must finish its pivotal dog trials, submit a complete NADA, and clear CVM review before the 2028 cutoff. CVM has already accepted Loyal’s reasonable-expectation-of-effectiveness path, a major de-risking uncommon for novel longevity claims. Veterinary approvals can take years after submission; a pivotal-trial failure or CVM demand for longer survival data would sharply lower odds.

Answer

Grok (xAI): 18% — Full CVM NADA for a lifespan-extension claim needs completed efficacy data Loyal cannot yet have. Loyal (and peers) still lack multi-year survival endpoints; CVM full approval, unlike conditional, requires them. Vet NADA review after complete package averages 12–18 months; only 14 months remain to 31 Dec 2027. No prior anti-aging indication has ever been approved; a surprise early biomarker-only filing would most raise the odds.

Answer

DeepSeek (DeepSeek): 12% — Loyal's LOY-002 must clear a large FDA effectiveness trial and CVM review in roughly two years, a pace no canine lifespan drug has ever hit. Loyal's LOY-002 has a conditional CVM approval for a 'maintains vitality' claim, not lifespan; full approval needs the ongoing 1,000-dog effectiveness study to read out… The FDA has never approved any drug for extending lifespan in any species, so there is no precedent pathway or timeline to anchor on; CVM review alone typically runs… The single development that would most change my mind is a completed pivotal trial with a statistically significant lifespan endpoint and an accepted NADA filing before…

Answer

Qwen (Alibaba): 24% — Hinges entirely on whether Loyal's LOY-001 field trial data is already submitted or imminent for FDA CVM review. Loyal received FDA CVM's reasonable expectation of effectiveness in early 2023 but original 2025-2026 approval targets have clearly slipped, signaling trial or data… FDA CVM NADA review typically takes 6-12 months post-submission, so approval by end-2027 requires submission by roughly mid-2027 at the latest. No other company is close enough to challenge Loyal's timeline; a surprise entrant getting full approval in 14 months is essentially zero probability.

A longevity or anti-aging drug for domestic dogs receives full regulatory approval before 2028.

A therapeutic treatment demonstrating clinically verified biological age reversal in humans receives FDA approval before 2035.

The FDA approves AbbVie's Biologics License Application for etentamig.

A clinical trial begins testing a vascularized, 3D-bioprinted human organ in patients before 2032.

A fully lab-grown solid human organ is successfully transplanted into a patient before 2035.